NEW YORK (GenomeWeb News) - Sloning Biotechnology and BioMérieux will collaborate on a feasibility study to develop gene variants for an enzyme BioMérieux can use in its in vitro diagnostics development programs, Sloning said today.

 

Sloning, based in Munich, Germany, said it will use its Slonomics gene-synthesis technology to offer BioMérieux “a gene library with a full set of ratio-controlled mutants.”